InSCREENeX Appoints Henrik L. Luessen as Chief Business Officer

17-Jun-2010 - Germany

InSCREENeX GmbH announced the appointment of Dr. Henrik L. Luessen to the position of Chief Business Officer. He will be responsible for business and strategic development with a particular focus on launching the company’s SCREENflex™ and CI-SCREEN™ technologies which can significantly improve biopharmaceutical drug discovery and validation.

Henrik L. Luessen brings more than 10 years of business development and strategic planning experience within the biopharmaceutical industry to InSCREENeX. He is founder and Managing Director of Tytonis B.V., a partner within a group of highly experienced, independent advisors providing a broad range of strategic, corporate and business development services to emerging life-science companies (www.tytonis.com). In this role, he supported InSCREENeX during the spin-off process last year.

Besides his roles as Chief Business Officer of InSCREENeX and Managing Director of Tytonis, Dr. Luessen also acts as Chief Business Officer of Activaero GmbH. Prior to founding Tytonis, he worked as Director Business Development at OctoPlus (EuroNext: OCTO), which he helped to develop from a group of 16 employees to a 130 people market leader in biopharmaceutical product development until their IPO in 2006. Before OctoPlus, Henrik L. Luessen was Manager Corporate Development at LTS LOHMANN Therapie Systeme AG, responsible for business development in the field of transdermal delivery systems and new platform technologies worldwide. He obtained his PhD from the Leiden/Amsterdam Center of Drug Research in Pharmaceutical Technology. He is heading the focus group »Pharmaceutical Biotechnology« at the International Association of Pharmaceutical Technology, Germany (APV) and has been serving as Governor of the Executive Board of the European Association of Pharmaceutical Biotechnology (EAPB) since December 2003.

Other news from the department people

More news from our other portals

So close that even
molecules turn red...